Tardive Dyskinesia News and Research

RSS
Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may appear as though the patient is playing an invisible guitar or piano.
Medicure announces results of operations for the three months ended August 31, 2009

Medicure announces results of operations for the three months ended August 31, 2009

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Final results of SAPHRIS clinical study released

Final results of SAPHRIS clinical study released

METOZOLV drug approved for treating gastroesophageal reflux disease

METOZOLV drug approved for treating gastroesophageal reflux disease

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

Biovail acquires worldwide rights to Tetrabenazine

Biovail acquires worldwide rights to Tetrabenazine

Seroquel XR supplemental NDA recommended for approval

Seroquel XR supplemental NDA recommended for approval

FDA approves Symbyax for treatment-resistant depression

FDA approves Symbyax for treatment-resistant depression

FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs

FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate shows positive results for treatment of schizophrenia

Expert warns of anti-psychotic drugs use in children

Expert warns of anti-psychotic drugs use in children

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

FDA approves INVEGA treatment for schizophrenia

FDA approves INVEGA treatment for schizophrenia

Older schizophrenia drugs cheaper and work just as well

Older schizophrenia drugs cheaper and work just as well

Functional genomics provide improved drug discovery

Functional genomics provide improved drug discovery